Search results for "Hemophilia"

showing 10 items of 94 documents

Recombinant factor VIII: past, present and future of treatment of hemophilia A.

2018

The development of recombinant factor VIII (rFVIII) was initially driven by the necessity to treat hemophilia A (HA) patients with FVIII concentrates without the risk of transmitting infectious agents. Over the last three decades the safety of rFVIII has been further improved by completely removing animal or human proteins from the manufacturing process, so that patients would not be exposed to known or emerging pathogens. Recent efforts have concentrated on improving the expression of rFVIII, reducing its immunogenicity and enhancing its pharmacokinetic (PK) behavior. These new goals have been possible thanks to the develop-ment of biotechnology and a better knowledge of the function and s…

0301 basic medicine030204 cardiovascular system & hematologyPharmacologyStandard half-life FVIIIHemophilia ARecombinant factor viiiHemostaticslaw.inventionCoagulation factor disorder03 medical and health sciences0302 clinical medicineHemostaticlawExtended half-life FVIIIMedicineHumansPharmacology (medical)Mode of actionPharmacologyFactor VIIIbiologybusiness.industryManufacturing processImmunogenicityHuman cellRecombinant ProteinRecombinant FVIIIRecombinant Proteins030104 developmental biologyTreatment OutcomeConsumer Product Safetybiology.proteinRecombinant DNAPEGylationAntibodybusinessDrug ContaminationHumanHalf-LifeDrugs of today (Barcelona, Spain : 1998)
researchProduct

Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia.

2008

Co-morbidities of haemophilia, such as arthropathy and blood-borne infections, can adversely affect the quality of life of adult patients with haemophilia. The purpose of this study was to develop and validate a haemophilia-specific health-related quality of life questionnaire for adults (HAEMO-QoL-A). Subjects with varying severities of haemophilia completed the HAEMO-QoL-A at baseline and 4 weeks. Other assessments included the SF-36 and Health Assessment Questionnaire - Functional Disability Index (HAQ-FDI). Two-hundred and twenty-one participants completed the 41-item HAEMO-QoL-A covering six domains (Physical Functioning, Role Functioning, Worry, Consequences of Bleeding, Emotional Imp…

AdultCross-Cultural ComparisonMalemedicine.medical_specialtyActivities of daily livingPsychometricsPsychometricsIntraclass correlationmedia_common.quotation_subjectConcurrent validityHIV InfectionsHaemophiliaHemophilia AYoung AdultQuality of lifeCronbach's alphaActivities of Daily LivingmedicineHumansGenetics (clinical)media_commonbusiness.industryHematologyGeneral MedicineMiddle Agedmedicine.diseasehumanitiesPhysical therapyQuality of LifeWorrybusinessEpidemiologic MethodsAttitude to HealthHaemophilia : the official journal of the World Federation of Hemophilia
researchProduct

The important impact of dental care on haemostatic treatment burden in patients with mild haemophilia

2022

Background: Mild haemophilia (MH) is mainly characterized by haemorrhages secondary to surgery/invasive procedures or trauma. Haemostatic treatment in MH ranges from on demand to short prophylaxis according to the type of bleeding events and the basal clotting factor level. Oral surgery and dental extractions can represent a frequent haemostatic challenge in MH requiring appropriate treatment. However, only few studies on limited numbers of patients are available in the literature regarding the implications of dental management in patients with MH. Objectives: The purpose of the study was to evaluate the impact of dental care on the burden of haemostatic treatment in patients affected by MH…

AdultMaleAged 80 and overFactor VIIIAdolescentHemorrhageHematologyGeneral MedicineMiddle AgedHemophilia Amild haemophilia dental care FVIII FIX haemophilia treatmentHemostaticsAntifibrinolytic AgentsBlood Coagulation FactorsYoung AdultHumansDental CareGenetics (clinical)Aged
researchProduct

New data from the Italian National Register of Congenital Coagulopathies, 2016 Annual Survey

2018

BACKGROUND: In Italy, the National Register of Congenital Coagulopathies (NRCC) collects epidemiological and therapeutic data from patients affected by haemophilia A (HA), haemophilia B (HB), von Willebrand’s disease (vWD) and other rare coagulation disorders. Here we present data from the 2016 annual survey. MATERIALS AND METHODS: Data are provided by the Italian Haemophilia Centres, on a voluntary basis. Information flows from every Centre to a web-based platform of the Italian Association of Haemophilia Centres, shared with the Italian National Institute of Health, in accordance with current privacy laws. Patients are classified by diagnosis, disease severity, age, gender and treatment-r…

AdultMaleCanadaAdolescentAdolescent Adult Aged Blood Coagulation Factors Canada Child Coagulation Protein Disorders Factor IX Factor VIII Female France HIV Infections Hemophilia A Hemophilia B Hepatitis CHumans Infant Infant Newborn Italy Male Middle Aged Prevalence Registries Surveys and Questionnaires United Kingdom von Willebrand DiseasesHIV InfectionsCoagulation Protein DisordersHemophilia AHemophilia BFactor IXhemic and lymphatic diseasesSurveys and QuestionnairesPrevalenceHumansRegistriesChildAgedFactor VIIIInfant NewbornInfantMiddle AgedHepatitis CBlood Coagulation FactorsUnited Kingdomvon Willebrand DiseasesItalyChild PreschoolFemaleOriginal ArticleFrance
researchProduct

Effectiveness of rehabilitation on pain and function in people affected by hemophilia

2021

Introduction: Literature provides unclear evidence of the effectiveness of many physiotherapy interventions on pain intensity, quality of life, and functional ability in hemophilic patients, and suggests that rehabilitation programs should be focused on functional goals and the disability of patients. Aim: The aim of the present study is to present the outcome of a case series of patients with hemophilia in which a rehabilitation program has been carried out on the basis of a specific individual patient’s functional impairment. Methods: Fifty-one patients were enrolled: 32 patients (Rehab Group) received a rehabilitative treatment, 19 patients for different reasons (living far from the hosp…

AdultMaleGeneral MedicineMiddle AgedHemophilia AExercise TherapyTreatment OutcomeMusculoskeletal PainQuality of LifeHumansFemaleRange of Motion ArticularErratumPain Measurementarthritis hemophilia musculoskeletal rehabilitation pain
researchProduct

Increased frequency of the CTLA-4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls

2007

Acquired haemophilia (AH) is an autoimmune disorder characterized by autoantibodies against endogenous factor VIII (FVIII). Half of the patients present with an underlying disease known to cause the FVIII autoantibodies whereas in the other half the disease is of idiopathic nature. Recently, it has been shown that variants of the polymorphic cytotoxic T lymphocyte antigen-4 (CTLA-4) gene are associated with autoimmune diseases and also represent a risk factor for inhibitor formation in inherited haemophilia A. In the present study, we investigated whether CTLA-4 variants also play a role in the pathogenesis of AH. Therefore, we analyzed three single nucleotide polymorphisms (SNPs) of the CT…

AdultMaleGenotypeSingle-nucleotide polymorphismHemophilia AHaemophiliaPolymorphism Single NucleotideGene FrequencyAntigens CDGenotypemedicineHumansCTLA-4 AntigenGenetic Predisposition to DiseaseAlleleAllele frequencyGenetics (clinical)AgedAutoantibodiesAged 80 and overAutoimmune diseaseFactor VIIIbusiness.industryAutoantibodyHematologyGeneral MedicineMiddle Agedmedicine.diseaseAntigens DifferentiationCase-Control StudiesImmunologyFemaleGene polymorphismbusinessHaemophilia
researchProduct

Correlation of hepatitis B virus, hepatitis D virus and human immunodeficiency virus type I infection markers in hepatitis B surface antigen positive…

1992

The hepatitis D virus (HDV) infection plays a major role in severe liver damage caused by hepatitis. To establish the prevalence of HDV infection in haemophilic patients and patients without haemophilia, 87 patients with chronic hepatitis B virus (HBV) infection were examined for serological evidence of delta hepatitis. In addition HBV, HDV and human immunodeficiency virus type 1 (HIV) infection markers were compared to clinical and histopathological outcome of hepatitis. Out of 46 haemophiliacs 30 (65%) were anti-HD-seropositive; 10 out of 30 anti-HD-positive patients (33%) had pathological liver function tests compared to 2 out of 16 anti-HD-negative haemophiliacs (13%). The rate of HIV i…

AdultMaleHepatitis B virusCirrhosisAdolescentvirusesBiopsyRadioimmunoassaymedicine.disease_causeHaemophiliaHemophilia AmedicineHumansHepatitis AntibodiesHepatitis B e AntigensChildAntigens ViralHepatitis ChronicHepatitis B virusHepatitisAcquired Immunodeficiency SyndromeHepatitis B Surface Antigensbiologymedicine.diagnostic_testbusiness.industryvirus diseasesMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis BVirologyHepatitis DHepatitis DHepadnaviridaeLiverLiver biopsyChild PreschoolPediatrics Perinatology and Child HealthDNA ViralHepatitis D virusHepatitis Delta VirusbusinessEuropean journal of pediatrics
researchProduct

Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in pati…

2012

Summary Von Willebrand disease (VWD) is an inherited bleeding disorder caused by the quantitative or qualitative deficiency of von Willebrand factor (VWF). Replacement therapy with plasma-derived VWF/factor VIII (FVIII) concentrates is required in patients unresponsive to desmopressin. To assess the efficacy, safety and ease of use of a new, volume-reduced (VR) formulation of VWF/FVIII concentrate Haemate® P in patients requiring treatment for bleeding or prophylaxis for recurrent bleeding or for invasive procedures. Pharmacoeconomic variables were also recorded. Data were analysed using descriptive statistics. This was a multicentre, prospective, observational study. Consecutively enrolled…

AdultMalePediatricsmedicine.medical_specialtyAdolescentBlood Loss SurgicalSevere diseaseHemorrhageSettore MED/15 - Malattie Del SangueYoung AdultVon Willebrand factorCost of Illnesshemic and lymphatic diseaseshemophiliavon Willebrand FactorVon Willebrand diseasemedicineHumansIn patientProspective StudiesDesmopressinAdverse effectChildGenetics (clinical)AgedFactor VIIIbiologybusiness.industryDrug SubstitutionAnticoagulantsHematologyGeneral MedicineMiddle Agedmedicine.diseaseResponse to treatmentHospitalizationvon Willebrand DiseasesItalyChild Preschoolbiology.proteinPasteurizationObservational studyFemalebusinessmedicine.drug
researchProduct

Secondary prophylaxis vs. on-demand treatment to improve quality of life in severe adult haemophilia A patients: a prospective study in a single cent…

2013

Background Retrospective publications show a decrease in the bleeding frequency and an improvement in the quality of life (QoL) in severe adult haemophilia A (SAHA) after switching from the on-demand treatment (DT) to secondary prophylaxis (SP). But there are no prospective studies which demonstrate, using a haemophilia-specific questionnaire, an improvement in the QoL after such treatment change. The main objective of this study is to prospectively compare the QoL and the musculoskeletal assessment after switching from DT to SP in SAHA using the A36 Hemofilia-QoL®. As secondary objective, we compare the haemarthrosis frequency and factor VIII consumption in DT and SP during a similar perio…

AdultMalePediatricsmedicine.medical_specialtyHaemophilia Ahaemophilia AHemorrhageHemophilia AQuality of lifeSurveys and QuestionnairesHemarthrosismedicineHumansProspective StudiesProspective cohort studyRetrospective StudiesmusculoskeletalFactor VIIIbusiness.industrySecondary prophylaxisHematologyGeneral MedicineMiddle Agedmedicine.diseasehumanitiesbleeding incidenceSingle centreOn demand treatmentquality of lifesecondary prophylaxisQuality of LifeFemalebusinessVox sanguinis
researchProduct

Predictive factors of immune tolerance treatment response in severe haemophilia A patients with inhibitors: A real‐world report from a single centre,…

2019

AdultMalePediatricsmedicine.medical_specialtyTreatment responseOnline LettersMEDLINEHemophilia AImmune toleranceHumansMedicineProspective StudiesTreatment FailureChildLetters to the EditorProspective cohort studyLetter to the EditorGenetics (clinical)Retrospective StudiesFactor VIIIbusiness.industryRetrospective cohort studyHematologyGeneral MedicineSingle centreLong term learningFemaleSevere haemophilia AbusinessHaemophilia
researchProduct